GeoVax Labs Inc
GOVX0.745USD
+0.020+2.76%
Market hours （ET）Quotes delayed by 15 min
11.86MMarket Cap
LossP/E TTM
More Details of GeoVax Labs Inc Company
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
Company Info
Ticker SymbolGOVX
Company nameGeoVax Labs Inc
IPO dateApr 04, 1994
CEOMr. David A. Dodd
Number of employees17
Security typeOrdinary Share
Fiscal year-endApr 04
Address1900 Lake Park Drive
CitySMYRNA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code30080
Phone16783847220
Websitehttps://www.geovax.com/
Ticker SymbolGOVX
IPO dateApr 04, 1994
CEOMr. David A. Dodd
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Dodd
Mr. David A. Dodd
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.66K
--
Mr. Mark W. Reynolds, CPA
Mr. Mark W. Reynolds, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
14.01K
+94.27%
Dr. Robert T. McNally, Ph.D.
Dr. Robert T. McNally, Ph.D.
Independent Director
Independent Director
3.60K
--
Dr. Randal D. Chase, Ph.D.
Dr. Randal D. Chase, Ph.D.
Independent Director
Independent Director
2.44K
--
Mr. Dean G. Kollintzas
Mr. Dean G. Kollintzas
Independent Director
Independent Director
800.00
--
Dr. Kelly T. Mckee, M.D.
Dr. Kelly T. Mckee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jayne Morgan, M.D.
Dr. Jayne Morgan, M.D.
Independent Director
Independent Director
--
--
Dr. Mark J. Newman, Ph.D.
Dr. Mark J. Newman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John N. (Jack) Spencer, Jr.
Mr. John N. (Jack) Spencer, Jr.
Independent Director
Independent Director
--
--
Dr. John W. Sharkey, Ph.D.
Dr. John W. Sharkey, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Dodd
Mr. David A. Dodd
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.66K
--
Mr. Mark W. Reynolds, CPA
Mr. Mark W. Reynolds, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
14.01K
+94.27%
Dr. Robert T. McNally, Ph.D.
Dr. Robert T. McNally, Ph.D.
Independent Director
Independent Director
3.60K
--
Dr. Randal D. Chase, Ph.D.
Dr. Randal D. Chase, Ph.D.
Independent Director
Independent Director
2.44K
--
Mr. Dean G. Kollintzas
Mr. Dean G. Kollintzas
Independent Director
Independent Director
800.00
--
Dr. Kelly T. Mckee, M.D.
Dr. Kelly T. Mckee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
5.82%
Armistice Capital LLC
2.61%
The Vanguard Group, Inc.
0.45%
Geode Capital Management, L.L.C.
0.38%
UBS Switzerland AG
0.31%
Other
90.43%
Shareholders
Shareholders
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
5.82%
Armistice Capital LLC
2.61%
The Vanguard Group, Inc.
0.45%
Geode Capital Management, L.L.C.
0.38%
UBS Switzerland AG
0.31%
Other
90.43%
Shareholder Types
Shareholders
Proportion
Corporation
5.82%
Hedge Fund
2.69%
Investment Advisor
0.93%
Investment Advisor/Hedge Fund
0.50%
Individual Investor
0.49%
Bank and Trust
0.31%
Research Firm
0.22%
Other
89.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
48
1.25M
5.13%
+94.59K
2025Q1
48
1.22M
8.27%
+83.76K
2024Q4
47
829.80K
9.13%
+330.71K
2024Q3
46
493.58K
6.02%
-230.53K
2024Q2
44
230.87K
6.14%
-94.40K
2024Q1
48
277.50K
12.08%
-7.33K
2023Q4
47
235.03K
12.03%
+67.17K
2023Q3
51
129.03K
7.28%
-172.28K
2023Q2
50
129.35K
7.40%
-168.66K
2023Q1
50
126.42K
8.79%
-177.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
662.88K
2.63%
+167.30K
+33.76%
Mar 31, 2025
The Vanguard Group, Inc.
115.16K
0.46%
+64.01K
+125.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
97.04K
0.39%
+6.90K
+7.66%
Mar 31, 2025
UBS Switzerland AG
77.64K
0.31%
+65.10K
+519.30%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
75.12K
0.3%
+75.00K
+62500.00%
Mar 31, 2025
Dodd (David A)
36.66K
0.24%
--
--
Jun 25, 2025
BlackRock Institutional Trust Company, N.A.
27.57K
0.11%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
27.05K
0.11%
+27.05K
--
Mar 31, 2025
Jane Street Capital, L.L.C.
25.83K
0.1%
+25.83K
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Date
Type
Ratio
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
